



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Panitumumab

March 24, 2015

Non-proprietary name

Panitumumab (genetical recombination)

Safety measure

Precautions should be revised in the package insert.

In the Clinically significant adverse reactions subsection of the Adverse reactions section, the following texts should be added (underlined parts are revised):

Oculomucocutaneous syndrome (Stevens–Johnson syndrome):

Oculomucocutaneous syndrome may occur. Patients should be carefully monitored. If any abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be taken.

NOTE

- This drug is designated to prepare a Drug Guide for Patients.